Eli Lilly, Pfizer celebrate a PhIII success for their blockbuster pain drug contender tanezumab — but questions linger

Five years after Eli Lilly stepped up with a $1.8 billion deal to bring Pfizer’s anti-NGF pain drug tanezumab back from limbo, the pharma giants are reporting that they successfully navigated a major Phase III study for the non-opioid therapy among patients suffering from osteoarthritis.